Meridian Bioscience (LSE:0K0K) - Cotización, noticias y análisis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Resumen de acción 0K0K

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.

Acerca de la empresa

0K0K fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Recompensas

Trading at 26.4% below our estimate of its fair value

Análisis de riesgos

Shares are highly illiquid

Large one-off items impacting financial results

Profit margins (12.7%) are lower than last year (22.5%)

Competidores de Meridian Bioscience, Inc.

Advanced Medical Solutions Group

AIM:AMS

UK£407.7m

ConvaTec Group

LSE:CTEC

UK£5.8b

Tristel

AIM:TSTL

UK£211.5m

CVS Group

AIM:CVSG

UK£680.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Meridian Bioscience
Historical stock prices
Current Share Price	US$33.97
52 Week High	US$33.97
52 Week Low	US$20.48
Beta	0.23
1 Month Change	2.13%
3 Month Change	6.07%
1 Year Change	59.66%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	137.55%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0K0K	GB Medical Equipment	Mercado GB
7D	0.7%	-0.09%	-0.9%
1Y	59.7%	-10.7%	-1.8%

Rentabilidad vs. Industria: 0K0K exceeded the UK Medical Equipment industry which returned -9.6% over the past year.

Rentabilidad vs. Mercado: 0K0K exceeded the UK Market which returned -5.6% over the past year.

Volatilidad de los precios

Is 0K0K's price volatile compared to industry and market?
0K0K volatility
0K0K Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0K0K has not had significant price volatility in the past 3 months.

Volatilidad a lo largo del tiempo: Insufficient data to determine 0K0K's volatility change over the past year.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1976	704	Jack Kenny	www.meridianbioscience.com

Resumen de fundamentos de Meridian Bioscience, Inc.

¿Cómo se comparan los beneficios e ingresos de Meridian Bioscience con su capitalización de mercado?
Estadísticas fundamentales de 0K0K
Capitalización bursátil	US$1.49b
Beneficios(TTM)	US$42.46m
Ingresos (TTM)	US$333.02m

35.2x

Ratio precio-beneficio (PE)

4.5x

Ratio precio-ventas (PS)

¿Está 0K0K sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0K0K
Ingresos	US$333.02m
Coste de los ingresos	US$144.66m
Beneficio bruto	US$188.36m
Otros gastos	US$145.90m
Beneficios	US$42.46m

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.96
Margen bruto	56.56%
Margen de beneficio neto	12.75%
Ratio deuda/patrimonio	6.8%

¿Cómo se ha desempeñado 0K0K a largo plazo?

Ver rendimiento histórico y comparativa

This company listing is no longer active

Resumen de acción 0K0K

Recompensas

Análisis de riesgos

Competidores de Meridian Bioscience, Inc.

AIM:AMS

UK£407.7m

LSE:CTEC

UK£5.8b

AIM:TSTL

UK£211.5m

AIM:CVSG

UK£680.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Insufficient new directors

Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021)

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Recent updates

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Insufficient new directors

Full year 2022 earnings released: EPS: US$0.97 (vs US$1.65 in FY 2021)

Meridian Bioscience, Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Impactive Capital Provides Information to Shareholders of Meridian Bioscience

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 profit in 3Q 2021)

Meridian Bioscience, Inc. Provides Update on Earnings Guidance for the Fiscal Year 2022

Meridian Bioscience, Inc. Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from Russell 2000 Value-Defensive Index

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience, Inc. Responds to the Monkeypox Outbreak with Its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience, Inc. Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Insufficient new directors

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Second Quarter of Fiscal 2022

Meridian Bioscience, Inc. Names Andy Kitzmiller as Executive Vice President

Magellan Diagnostics Resumes Distribution of Leadcare® II Test Kits

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Meridian Bioscience, Inc. Raises Earnings Guidance for the Full Fiscal Year 2022

Insufficient new directors

Meridian Bioscience Launches Lyo-Ready qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience, Inc. Announces Board Changes

Meridian Bioscience, Inc. Receives FDA-Clearance for the Curian® Campy Assay

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$1.65 (vs US$1.08 in FY 2020)

Insufficient new directors

Insufficient new directors

Meridian Bioscience, Inc. Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples

Third quarter 2021 earnings released: EPS US$0.27 (vs US$0.64 in 3Q 2020)

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides Preliminary Revenue Guidance for the Third Quarter of Fiscal 2021

Meridian Bioscience, Inc. Announces Launch of the Lyo-Ready RT-LAMP Mix

Meridian Bioscience, Inc. Improves Field-Testing in AgBio with its New Air-Dryable™ qPCR Mix for Crude Plant Samples

Meridian Bioscience, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Second quarter 2021 earnings released: EPS US$0.61 (vs US$0.22 in 2Q 2020)

Meridian Bioscience, Inc. Announces the Launch of the Lyo-Ready DNA LAMP Mix

Investor sentiment deteriorated over the past week

President recently sold US$250k worth of stock

Investor sentiment improved over the past week

Meridian Bioscience, Inc. Announces the Launch of New Air-Dryable Direct DNA qPCR Blood Mix

Meridian Bioscience Provides A Further Update on the Revogene® Sars-Cov-2 Eua Submission

Investor sentiment deteriorated over the past week

Meridian Bioscience, Inc. Provides an Update on the Revogene SARS-CoV-2 EUA Submission

First quarter 2021 earnings released: EPS US$0.62 (vs US$0.066 in 1Q 2020)

Revenue beats expectations

Investor sentiment improved over the past week

Meridian Bioscience, Inc. Raises Consolidated Earnings Guidance for the Fiscal Year 2021

Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays

Meridian Bioscience, Inc. to Report Q1, 2021 Results on Feb 05, 2021

Meridian Bioscience, Inc., Annual General Meeting, Jan 27, 2021

Market pulls back on stock over the past week

Meridian Bioscience, Inc. Launches Its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

Independent Director recently bought US$88k worth of stock

Market pulls back on stock over the past week

Full year 2020 earnings released: EPS US$1.08

Revenue beats expectations